{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:01Z","timestamp":1790186521833,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2024.10.031","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T18:22:16Z","timestamp":1731090136000},"page":"497-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Home Optical Coherence Tomography and Sustained Delivery Approaches: A Perfect Marriage"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-8515","authenticated-orcid":false,"given":"Nancy M.","family":"Holekamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2024.10.031_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.7647","article-title":"The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration","volume":"132","author":"Sloan","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2024.10.031_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.10.031_bib0003","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ophtha.2014.12.007","article-title":"Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic whites with diabetic macular edema in the United States","volume":"122","author":"Varma","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.10.031_bib0004","unstructured":"Notal Vision. Accessed August 1, 2024. https:\/\/notalvision.com\/services\/scanly-oct."},{"key":"10.1016\/j.ajo.2024.10.031_bib0005","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.oret.2022.02.011","article-title":"Prospective, longitudinal study: daily self-imaging with Home OCT for neovascular age-related macular degeneration","volume":"6","author":"Liu","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"10.1016\/j.ajo.2024.10.031_bib0006","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/IAE.0000000000004167","article-title":"Prospective trial of Home OCT guided management of treatment experienced nAMD patients","volume":"44","author":"Holekamp","year":"2024","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.ajo.2024.10.031_bib0007","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s40123-024-00999-8","article-title":"Economic assessment in resource-constrained systems: individual-level simulation model in wet age-related macular degeneration and diabetic macula oedema","volume":"13","author":"Li","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ajo.2024.10.031_bib0008","article-title":"Retinal fluid and thickness fluctuations in archway trial for port delivery system with ranibizumab versus monthly ranibizumab injections","author":"Sheth","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.ajo.2024.10.031_bib0009","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.10.031_bib0010","article-title":"Interim results of the phase III portal extension trial of the port delivery system with ranibizumab in neovascular age-related macular degeneration","author":"Campochiaro","year":"2024","journal-title":"Ophthalmology Retina"},{"issue":"8","key":"10.1016\/j.ajo.2024.10.031_bib0011","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.10.031_bib0012","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41433-023-02610-z","article-title":"Tyrosine kinase inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema","volume":"37","author":"Chandra","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajo.2024.10.031_bib0013","unstructured":"Ocular Therapeutix. Accessed August 3, 2024. https:\/\/investors.ocutx.com\/static-files\/9a2366eb-bf3f-45d8-b6f4-8aad4928c536."},{"key":"10.1016\/j.ajo.2024.10.031_bib0014","unstructured":"Eyepoint Pharmaceuticals. Accessed August 3, 2024.https:\/\/eyepointpharma.com\/wp-content\/uploads\/2024\/06\/Regillo-CTS-2024_DAVIO-2-6M_FINAL.pdf."},{"key":"10.1016\/j.ajo.2024.10.031_bib0015","unstructured":"Clearside Biomedical. Accessed August 3, 2024. https:\/\/clearsidebio.com\/wp-content\/uploads\/2024\/02\/OASIS-Extension-Study-Results-2.2.23.pdf."},{"key":"10.1016\/j.ajo.2024.10.031_bib0016","unstructured":"4DMT. Accessed August 3, 2024. https:\/\/4dmoleculartherapeutics.com\/wp-content\/uploads\/Presentation_ASRS-2024_Maturi_PRISM-Population-Extension_FINAL.pdf."}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:34:33Z","timestamp":1754919273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424005129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":16,"alternative-id":["S0002939424005129"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.10.031","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Home Optical Coherence Tomography and Sustained Delivery Approaches: A Perfect Marriage","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}